Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-10-25 , DOI: 10.1111/apt.16674
Hannah P Kim ₁ , Michael O Idowu ₂ , Andrea R Mospan ₃ , Andrew G Allmon ₃ , Michael Roden _{4,

5,

6} , Philip Newsome ₇ , Anna S Lok ₈ , Paul J Thuluvath _{9,

10} , Jawahar Taunk ₁₁ , Michael W Fried ₃ , Arun J Sanyal ₂ , A Sidney Barritt ₁ ,

Affiliation

Patients with non-alcoholic steatohepatitis (NASH) and fibrosis stage ≥2 comprise a target population for pharmacotherapy. Liver biopsy, the reference standard for identifying this population, requires complete and accurate assessment of steatohepatitis and fibrosis.

中文翻译：